Akero Therapeutics Analyst Ratings
Akero Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 186.74% | HC Wainwright & Co. | → $40 | Reiterates | Buy → Buy |
| 10/12/2023 | 179.57% | UBS | $83 → $39 | Maintains | Buy |
| 10/11/2023 | 193.91% | JP Morgan | $62 → $41 | Maintains | Overweight |
| 10/11/2023 | 186.74% | HC Wainwright & Co. | $64 → $40 | Maintains | Buy |
| 10/11/2023 | 179.57% | Cantor Fitzgerald | $69 → $39 | Maintains | Overweight |
| 10/11/2023 | 136.56% | Morgan Stanley | $70 → $33 | Maintains | Overweight |
| 10/04/2023 | 394.62% | Cantor Fitzgerald | → $69 | Reiterates | Overweight → Overweight |
| 09/19/2023 | 394.62% | Cantor Fitzgerald | → $69 | Initiates Coverage On | → Overweight |
| 09/13/2023 | 330.11% | Evercore ISI Group | $50 → $60 | Maintains | Outperform |
| 09/05/2023 | 344.44% | JP Morgan | $49 → $62 | Maintains | Overweight |
| 08/28/2023 | 494.98% | UBS | → $83 | Initiates Coverage On | → Buy |
| 06/12/2023 | 401.79% | Morgan Stanley | $65 → $70 | Maintains | Overweight |
| 06/07/2023 | 358.78% | HC Wainwright & Co. | $62 → $64 | Maintains | Buy |
| 05/17/2023 | 322.94% | Canaccord Genuity | $58 → $59 | Maintains | Buy |
| 05/16/2023 | 344.44% | HC Wainwright & Co. | $64 → $62 | Maintains | Buy |
| 03/21/2023 | 315.77% | Canaccord Genuity | $50 → $58 | Maintains | Buy |
| 03/20/2023 | 358.78% | HC Wainwright & Co. | → $64 | Reiterates | → Buy |
| 01/27/2023 | 365.95% | Morgan Stanley | → $65 | Upgrades | Equal-Weight → Overweight |
| 11/07/2022 | 186.74% | Morgan Stanley | $30 → $40 | Maintains | Equal-Weight |
| 11/07/2022 | 358.78% | HC Wainwright & Co. | $62 → $64 | Maintains | Buy |
| 09/14/2022 | 115.05% | Morgan Stanley | $26 → $30 | Maintains | Equal-Weight |
| 09/14/2022 | 258.42% | Evercore ISI Group | $10 → $50 | Upgrades | In-Line → Outperform |
| 11/15/2021 | 107.89% | Morgan Stanley | $27 → $29 | Maintains | Equal-Weight |
| 11/15/2021 | 344.44% | HC Wainwright & Co. | $64 → $62 | Maintains | Buy |
| 10/19/2021 | 93.55% | Morgan Stanley | → $27 | Downgrades | Overweight → Equal-Weight |
| 09/10/2021 | 186.74% | B of A Securities | → $40 | Initiates Coverage On | → Buy |
| 08/16/2021 | 358.78% | HC Wainwright & Co. | $68 → $64 | Maintains | Buy |
| 03/23/2021 | 351.61% | Morgan Stanley | $70 → $63 | Maintains | Overweight |
| 03/23/2021 | 387.46% | HC Wainwright & Co. | $61 → $68 | Maintains | Buy |
| 03/18/2021 | 229.75% | Canaccord Genuity | $51 → $46 | Maintains | Buy |
| 03/17/2021 | 480.65% | Chardan Capital | $79 → $81 | Maintains | Buy |
| 03/17/2021 | 337.28% | HC Wainwright & Co. | $64 → $61 | Maintains | Buy |
| 02/26/2021 | 287.1% | Guggenheim | → $54 | Initiates Coverage On | → Buy |
| 11/13/2020 | 358.78% | HC Wainwright & Co. | $62 → $64 | Maintains | Buy |
| 09/10/2020 | 401.79% | Morgan Stanley | → $70 | Initiates Coverage On | → Overweight |
| 07/20/2020 | 344.44% | HC Wainwright & Co. | $45 → $62 | Maintains | Buy |
| 07/07/2020 | 466.31% | Chardan Capital | → $79 | Initiates Coverage On | → Buy |
| 07/01/2020 | 222.58% | HC Wainwright & Co. | $33 → $45 | Maintains | Buy |
| 07/01/2020 | 244.09% | Jefferies | $31 → $48 | Maintains | Buy |
| 03/02/2020 | 136.56% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
| 02/10/2020 | 158.06% | Canaccord Genuity | → $36 | Initiates Coverage On | → Buy |
| 07/15/2019 | 100.72% | JP Morgan | → $28 | Initiates Coverage On | → Overweight |
| 07/15/2019 | 143.73% | Roth Capital | → $34 | Initiates Coverage On | → Buy |
| 07/15/2019 | 100.72% | Jefferies | → $28 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/14/2023 | 186.74% | HC Wainwright & Co. | → 40 美元 | 重申 | 購買 → 購買 |
| 2023 年 12 月 10 日 | 179.57% | 瑞銀（UBS） | 83 美元 → 39 美元 | 維護 | 買 |
| 2023 年 11 月 10 日 | 193.91% | 摩根大通 | 62 美元 → 41 美元 | 維護 | 超重 |
| 2023 年 11 月 10 日 | 186.74% | HC Wainwright & Co. | 64 美元 → 40 美元 | 維護 | 買 |
| 2023 年 11 月 10 日 | 179.57% | 坎託·菲茨傑拉德 | 69 美元 → 39 美元 | 維護 | 超重 |
| 2023 年 11 月 10 日 | 136.56% | 摩根士丹利 | 70 美元 → 33 美元 | 維護 | 超重 |
| 2023 年 4 月 10 日 | 394.62% | 坎託·菲茨傑拉德 | → 69 美元 | 重申 | 超重 → 超重 |
| 09/19/2023 | 394.62% | 坎託·菲茨傑拉德 | → 69 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 09/13/2023 | 330.11% | Evercore ISI 集團 | 50 美元 → 60 美元 | 維護 | 跑贏大盤 |
| 09/05/2023 | 344.44% | 摩根大通 | 49 美元 → 62 美元 | 維護 | 超重 |
| 08/28/2023 | 494.98% | 瑞銀（UBS） | → 83 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 06/12/2023 | 401.79% | 摩根士丹利 | 65 美元 → 70 美元 | 維護 | 超重 |
| 06/07/2023 | 358.78% | HC Wainwright & Co. | 62 美元 → 64 美元 | 維護 | 買 |
| 05/17/2023 | 322.94% | Canaccord Genu | 58 美元 → 59 美元 | 維護 | 買 |
| 05/16/2023 | 344.44% | HC Wainwright & Co. | 64 美元 → 62 美元 | 維護 | 買 |
| 03/21/2023 | 315.77% | Canaccord Genu | 50 美元 → 58 美元 | 維護 | 買 |
| 03/20/2023 | 358.78% | HC Wainwright & Co. | → 64 美元 | 重申 | → 購買 |
| 01/27/2023 | 365.95% | 摩根士丹利 | → 65 美元 | 升級 | 重量相等 → 超重 |
| 2022 年 7 月 11 日 | 186.74% | 摩根士丹利 | 30 美元 → 40 美元 | 維護 | 重量相等 |
| 2022 年 7 月 11 日 | 358.78% | HC Wainwright & Co. | 62 美元 → 64 美元 | 維護 | 買 |
| 09/14/2022 | 115.05% | 摩根士丹利 | 26 美元 → 30 美元 | 維護 | 重量相等 |
| 09/14/2022 | 258.42% | Evercore ISI 集團 | 10 美元 → 50 美元 | 升級 | 盤中 → 跑贏大盤 |
| 11/15/2021 | 107.89% | 摩根士丹利 | 27 美元 → 29 美元 | 維護 | 重量相等 |
| 11/15/2021 | 344.44% | HC Wainwright & Co. | 64 美元 → 62 美元 | 維護 | 買 |
| 10/19/2021 | 93.55% | 摩根士丹利 | → 27 美元 | 降級 | 超重 → 重量相等 |
| 2021 年 10 月 9 日 | 186.74% | B of A 類證券 | → 40 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 8 月 16 日 | 358.78% | HC Wainwright & Co. | 68 美元 → 64 美元 | 維護 | 買 |
| 03/23/2021 | 351.61% | 摩根士丹利 | 70 美元 → 63 美元 | 維護 | 超重 |
| 03/23/2021 | 387.46% | HC Wainwright & Co. | 61 美元 → 68 美元 | 維護 | 買 |
| 03/18/2021 | 229.75% | Canaccord Genu | 51 美元 → 46 美元 | 維護 | 買 |
| 03/17/2021 | 480.65% | 查丹資本 | 79 美元 → 81 美元 | 維護 | 買 |
| 03/17/2021 | 337.28% | HC Wainwright & Co. | 64 美元 → 61 美元 | 維護 | 買 |
| 2021 年 2 月 26 日 | 287.1% | 古根海姆 | → 54 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/13/2020 | 358.78% | HC Wainwright & Co. | 62 美元 → 64 美元 | 維護 | 買 |
| 2020 年 10 月 9 日 | 401.79% | 摩根士丹利 | → 70 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2020 年 7 月 20 日 | 344.44% | HC Wainwright & Co. | 45 美元 → 62 美元 | 維護 | 買 |
| 07/07/2020 | 466.31% | 查丹資本 | → 79 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/01/2020 | 222.58% | HC Wainwright & Co. | 33 美元 → 45 美元 | 維護 | 買 |
| 07/01/2020 | 244.09% | 傑富瑞集團 | 31 美元 → 48 美元 | 維護 | 買 |
| 03/02/2020 | 136.56% | HC Wainwright & Co. | → 33 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 10 月 2 日 | 158.06% | Canaccord Genu | → 36 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/15/2019 | 100.72% | 摩根大通 | → 28 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 07/15/2019 | 143.73% | 羅斯資本 | → 34 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/15/2019 | 100.72% | 傑富瑞集團 | → 28 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Akero Therapeutics (AKRO)?
Akero Therapeutics（AKRO）的目標價格是多少？
The latest price target for Akero Therapeutics (NASDAQ: AKRO) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $40.00 expecting AKRO to rise to within 12 months (a possible 186.74% upside). 18 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月14日公佈了Akero Therapeutics（納斯達克股票代碼：AKRO）的最新目標股價。該分析公司將目標股價定爲40.00美元，預計AKRO將在12個月內升至12個月內（可能上漲186.74％）。去年有18家分析公司公佈了評級。
What is the most recent analyst rating for Akero Therapeutics (AKRO)?
Akero Therapeutics（AKRO）的最新分析師評級是多少？
The latest analyst rating for Akero Therapeutics (NASDAQ: AKRO) was provided by HC Wainwright & Co., and Akero Therapeutics reiterated their buy rating.
HC Wainwright & Co. 提供了Akero Therapeutics（納斯達克股票代碼：AKRO）的最新分析師評級，Akero Therapeutics重申了買入評級。
When is the next analyst rating going to be posted or updated for Akero Therapeutics (AKRO)?
Akero Therapeutics（AKRO）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akero Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Akero Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Akero Therapeutics的最新評級是在2023年11月14日公佈的，因此您應該預計下一個評級將在2024年11月14日左右公佈。
Is the Analyst Rating Akero Therapeutics (AKRO) correct?
分析師對Akero Therapeutics（AKRO）的評級是否正確？
While ratings are subjective and will change, the latest Akero Therapeutics (AKRO) rating was a reiterated with a price target of $0.00 to $40.00. The current price Akero Therapeutics (AKRO) is trading at is $13.95, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Akero Therapeutics（AKRO）評級，目標股價爲0.00美元至40.00美元。Akero Therapeutics（AKRO）目前的交易價格爲13.95美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。